• Wondering whether Stoke Therapeutics at around US$33.78 is starting to look expensive or if there is still value on the table? This article walks through the key numbers so you can judge for yourself.
• The stock has been volatile, with a 4.8% decline over the last 7 days, an 11.3% gain over 30 days, a 9.3% return year to date, a 345.6% return over 1 year, a 266.0% return over 3 years, and a 34.9% decline over 5 years.
• These price swings sit against a backdrop of ongoing attention on Stoke Therapeutics in the rare disease and genetic medicine space, as investors weigh the potential of its pipeline against the typical risks that come with early stage biotech companies. Recent coverage has focused on how clinical progress, regulatory updates, funding capacity and partnership activity might influence sentiment and help explain the strong moves over the last year.
• On our framework, Stoke Therapeutics currently scores 3 out of 6 on valuation. This reflects that it screens as undervalued on half of the checks we run, as shown by its 3/6 valuation score. Next we will look at how different valuation approaches line up and then finish with a broader way of thinking about what this score really means for you.

Approach 1: Stoke Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and discounting them back into present value using a required rate of return.

For Stoke Therapeutics, the model used here is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $. The latest twelve month free cash flow is about $50.5 million. Analyst estimates feed into the near term, and Simply Wall St extrapolates further out, with projected free cash flow of $174.5 million in 2030 and a series of projections through 2035, some of which are losses and some of which are positive cash flows.

Bringing all of those projected cash flows back to today gives an estimated intrinsic value of $256.13 per share, compared with a current share price of about $33.78. According to this model, that implies the shares trade at an 86.8% discount to the DCF estimate. This suggests that, on this specific cash flow view, Stoke Therapeutics appears undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Stoke Therapeutics is undervalued by 86.8%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Approach 2: Stoke Therapeutics Price vs Earnings

For a company that is generating earnings, the P/E ratio is a straightforward way to link what you pay for each share to the profit that share currently represents. It is widely used because it gives a quick sense of how much investors are willing to pay for a dollar of earnings.

The “right” P/E depends a lot on what the market expects for growth and how risky those earnings appear. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher uncertainty can mean a lower “normal” P/E is more appropriate.

Stoke Therapeutics currently trades on a P/E of 47.56x. That sits above the Biotechs industry average of 21.75x, but below the peer group average of 73.81x. Simply Wall St’s Fair Ratio for Stoke Therapeutics is 21.29x. This Fair Ratio is a proprietary estimate of what the P/E might be given the company’s earnings growth profile, industry, profit margins, market cap and key risks.

Compared with a simple peer or industry comparison, the Fair Ratio aims to be more tailored because it folds those company specific factors into a single benchmark. Setting the current P/E of 47.56x against the Fair Ratio of 21.29x points to the shares trading above that customised range.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Stoke Therapeutics Narrative

Earlier we mentioned that there is an even better way to understand valuation. Let us introduce you to Narratives, which are simply your own story for a company that links what you think about its medicines, markets and risks to a concrete forecast for revenue, earnings and margins, and then to a Fair Value that you can easily compare with the current share price on Simply Wall St’s Community page.

On the platform, millions of investors use Narratives as an accessible tool to turn their views into numbers, then see in real time whether those numbers point to the stock looking cheap or expensive. Because Narratives update automatically when new information like news or earnings arrives, you can quickly see how your thesis stacks up against fresh data.

For Stoke Therapeutics, one investor might build a Narrative that looks more like the higher analyst fair value of US$39.00, with assumptions that line up with the more optimistic targets. Another might lean closer to the lower US$24.00 view. By setting out both stories side by side, you can decide which assumptions feel more reasonable to you and what that implies for the gap between Fair Value and today’s price.

Do you think there's more to the story for Stoke Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.